Beta Nerve Growth Factor (Beta NGF or NGF)-Pipeline Review, H1 2017

Beta Nerve Growth Factor (Beta NGF or NGF)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0776TDB
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Beta Nerve Growth Factor (Beta NGF or NGF)-Pipeline Review, H1 2017

Summary

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF)-Pipeline Review, H1 2017, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF)-Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 5 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Toxicology which include indications Osteoarthritis Pain, Alzheimer's Disease, Cancer Pain, Low Back Pain, Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, Diabetic Neuropathy, Huntington Disease, Interstitial Cystitis (Painful Bladder Syndrome), Keratitis, Mild Cognitive Impairment, Optic Nerve Injury, Peripheral Nerve Injury and Post-Operative Pain.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)

The report reviews Beta Nerve Growth Factor (Beta NGF or NGF)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Beta Nerve Growth Factor (Beta NGF or NGF)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Beta Nerve Growth Factor (Beta NGF or NGF)-Overview

Beta Nerve Growth Factor (Beta NGF or NGF)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF)-Companies Involved in Therapeutics Development

Amgen Inc

Astellas Pharma Inc

Fujimoto Pharmaceutical Corp

Krenitsky Pharmaceuticals Inc

MedImmune LLC

NsGene A/S

Pfizer Inc

Regeneron Pharmaceuticals Inc

Serometrix LLC

Beta Nerve Growth Factor (Beta NGF or NGF)-Drug Profiles

AS-288640100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasinumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulranumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Optic Nerve Injury-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-544-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7352-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NsG-0202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Neurotrophic Keratitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NGF for Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Nerve Growth Factor (Beta NGF or NGF)-Dormant Products

Beta Nerve Growth Factor (Beta NGF or NGF)-Discontinued Products

Beta Nerve Growth Factor (Beta NGF or NGF)-Product Development Milestones

Featured News & Press Releases

Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs

May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain

Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain

Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors

Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909

Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug

Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program

Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab

May 12, 2010: Regeneron Provides Initial Data On REGN475

Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010

Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202

Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx

Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains

Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Amgen Inc, H1 2017

Pipeline by Astellas Pharma Inc, H1 2017

Pipeline by Fujimoto Pharmaceutical Corp, H1 2017

Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017

Pipeline by MedImmune LLC, H1 2017

Pipeline by NsGene A/S, H1 2017

Pipeline by Pfizer Inc, H1 2017

Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Pipeline by Serometrix LLC, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc, Astellas Pharma Inc, Fujimoto Pharmaceutical Corp, Krenitsky Pharmaceuticals Inc, MedImmune LLC, NsGene A/S, Pfizer Inc, Regeneron Pharmaceuticals Inc, Serometrix LLC

select a license

Single User License
USD 3500 INR 225960
Site License
USD 7000 INR 451920
Corporate User License
USD 10500 INR 677880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com